The FINANCIAL — A common treatment for wet age-related macular degeneration (AMD) may need a second thought by doctors of optometry. A new study suggests, in some cases, that patients’ vision worsens ...

STOCKHOLM — A real-world analysis of retrospective data showed that administering more anti-VEGF injections over a 5-year time span to treat macular edema secondary to retinal vein occlusion (RVO) was ...

Patients who received eye injections of anti-VEGF agents around the time of a stroke or myocardial infarction did not have an increased risk for mortality or major complications, and outcomes did not ...

If you have wet age-related macular degeneration (wet AMD) or another disease of the retina, your doctor may recommend treatment with an anti-VEGF drug. VEGF, or vascular endothelial growth factor, is ...

Please provide your email address to receive an email when new articles are posted on . Visual acuity increased by 3 letters on average at year 1. By year 6, annual decreases led to a net loss of 4.6 ...

Adverum Biotechnologies Inc (NASDAQ:ADVM) released data from its ongoing LUNA Phase 2 trial for Ixo-vec in patients with wet age-related macular degeneration (AMD). The 26-week interim analysis was ...

Anti–vascular endothelial growth factor (VEGF) medications have been a mainstay of treatment for wet age-related macular degeneration (wet AMD) for 20 years — and for good reason. The medication has ...

Diabetes can lead to vision complications, such as diabetic retinopathy and diabetic macular edema. Anti-VEGF injections can help protect your vision and may even improve your sight. The procedures ...

A low risk of adverse safety outcomes was observed in anti–vascular endothelial growth factor (VEGF) intravitreal injections performed in office-based and operating room settings, with a higher rate ...

Please provide your email address to receive an email when new articles are posted on . Mynampati and colleagues measured VEGF levels in 59 eyes of patients with diabetic retinopathy (DR) who had ...

In the study, researchers found that nearly one-quarter of anti-VEGF injections were received at least 1 week later than intended. Christina Y. Weng, MD, MBA, and colleagues compared the intended ...